Oculis Holding
Swiss/Icelandic ophthalmology biotech listed on Nasdaq (OCS). After the DIAMOND pivotal-trial failure (OCS-01 in diabetic macular oedema, 29 May 2026), Oculis is repositioning around neuro-ophthalmology with two assets in registrational trials: licaminlimab (OCS-02) in severe dry eye disease — PREDICT-1 topline expected around year-end 2026 — and privosegtor (OCS-05), a neuroprotective candidate whose programme is expanding from optic neuritis (PIONEER) to acute multiple sclerosis relapses (positive FDA pre-IND feedback in August 2026). In August 2026, Oculis signed the acquisition from Accure Therapeutics of full worldwide ownership of privosegtor (and the preclinical candidate ACT-02), moving from licensee to owner of its lead asset. Cash of $282.3M at 30 June 2026, stated runway into 2H 2029.
Investment thesis
- 01
Thesis recalibrated after the DIAMOND trial failure (OCS-01, DME) in May 2026: the lead candidate is dropped in DME, no FDA filing is planned, and investment value now rests on the two remaining assets.
- 02
OCS-02 (licaminlimab) — topical anti-TNFα antibody in the genotype-based registrational trial PREDICT-1 for severe dry eye disease: all sites activated, over 45% of patients randomized, topline results expected around year-end 2026 — the asset closest to a decisive readout.
- 03
OCS-05 (privosegtor) — small-molecule neuroprotective candidate in the PIONEER-1 registrational trial for acute optic neuritis under an FDA Special Protocol Assessment (primary endpoint: ≥15-letter gain in low-contrast visual acuity at Month 3), carrying FDA Breakthrough Therapy and EMA PRIME designations; first patient treated on 24 August 2026 — the trial is now in active enrolment (US, Europe, Australia, Canada).
- 04
Privosegtor expansion into acute multiple sclerosis relapses: positive pre-IND feedback from the FDA Division of Neurology (August 2026) — existing data can be cross-referenced, no additional preclinical studies required, IND submission targeted for Q4 2026. Large market (~2.8M MS patients worldwide, ~170,000 relapses/year in the US) with no approved neuroprotective option.
- 05
Full ownership of privosegtor: on 10 August 2026 Oculis signed an asset purchase agreement with Accure Therapeutics for all worldwide development and commercial rights to privosegtor (ACT-01) and the preclinical neurology candidate ACT-02. The deal ($3.8M cash + up to 2.05M shares, part contingent on milestones) terminates the prior license and its per-indication royalties / milestone payments: Oculis moves from licensee to owner of its lead asset, retaining only low single-digit academic royalties. Closings expected by 28 February 2027 (privosegtor) and 31 March 2027 (ACT-02).
- 06
Reading the OCS-01 signal: retinal thickness reduction was demonstrated and tolerability was acceptable, but with no clinical visual acuity benefit — Oculis explicitly stated no DME regulatory filing will be pursued.
- 07
Solid balance sheet: $282.3M in cash and investments at 30 June 2026, providing a stated runway into 2H 2029 — enough to fund PREDICT-1, PIONEER-1 and the clinical entry of the MS programme without near-term refinancing need.
- 08
Experienced management and board from the European ophthalmology industry; execution on PREDICT-1 and PIONEER will be the principal determinant of any re-rating after the May 2026 sell-off.
Catalysts
Privosegtor / ACT-02 acquisition closings (Accure)
APA signed on 10 August 2026; completion expected by 28 February 2027 (privosegtor) and 31 March 2027 (ACT-02, contingent on the first closing). Closing consolidates full ownership of the lead asset and removes the per-indication royalties / milestone payments owed to Accure.
PREDICT-1 (OCS-02 / licaminlimab) — dry eye topline results
The most advanced registrational trial: all sites activated and over 45% of patients randomized as of 30 June 2026; topline results expected around year-end 2026 — the principal value catalyst post-DIAMOND.
IND submission — privosegtor in acute MS relapses
Following positive FDA pre-IND feedback (August 2026), Oculis targets an IND submission in Q4 2026 for a new neurology indication, materially widening privosegtor's addressable market beyond ophthalmology.
PIONEER-1 (OCS-05 / privosegtor) — optic neuritis progression
First patient treated on 24 August 2026: the registrational trial (FDA Special Protocol Assessment, Month-3 primary endpoint; FDA Breakthrough Therapy and EMA PRIME designations) is now in active enrolment across the US, Europe, Australia and Canada — pace follows disease seasonality (fall-winter-spring).
Virtual R&D Day
Event announced for Q4 2026: a detailed pipeline update (PIONEER, MS programme, PREDICT-1) — a key opportunity to clarify timelines and the neuro-ophthalmology pivot strategy.
Market reading of the OCS-01 anatomical signal
Although regulatorily moot in DME, the retinal thickness signal could feed reflection on repurposing (other indication, other formulation, partnership) — to monitor in management communications.
Risks
Binary clinical risk — now materialised on OCS-01
The DIAMOND trial failure illustrates the binary risk inherent to a clinical-stage biotech. PREDICT-1 and PIONEER remain exposed to the same type of hazard, now without a buffer asset.
Thesis concentrated on two assets
After DIAMOND, fundamental value rests largely on the success of licaminlimab and privosegtor. Any failure on PREDICT-1 or PIONEER would have a disproportionate impact on valuation.
Cash and funding horizon
The $282.3M cash position (30 June 2026, stated runway into 2H 2029) pushes back near-term funding risk, but the widening pipeline (PIONEER-1, PREDICT-1, clinical entry of the MS programme) remains cash-consuming; a timeline slip or a negative readout could reopen the recapitalisation question.
Competitive landscape in ophthalmology
The dry eye market remains competitive (AbbVie, Bausch + Lomb, Novartis, Viatris). Licaminlimab's commercial positioning would still need to be demonstrated even after clinical success.
Nasdaq volatility and float
Nasdaq listing with limited float: price moves can be amplified by technical flows, as illustrated by the post-DIAMOND reaction.
Calendar
- 14–25 sept. 2026September investor conferences · H.C. Wainwright Annual Global Investment (14–16 Sept.; company update presented by CEO Riad Sherif on 14 Sept. at 9:30 a.m. ET), Baird 2026 Global Healthcare (15 Sept.; fireside chat with Riad Sherif, 3:45–4:15 p.m. ET), Leerink Biopharma Summit (23–25 Sept.; management team attending)Conference
- Fin 2026PREDICT-1 topline results (licaminlimab)Clinical
- 28 fév. 2027Privosegtor acquisition closing (ACT-01, at the latest)Corporate
- 31 mars 2027ACT-02 acquisition closing (at the latest)Corporate
- Q4 2026IND submission — privosegtor (acute MS relapses)Corporate
- Q4 2026Virtual R&D DayCorporate
- 2026-2027PIONEER-1 milestones (privosegtor, optic neuritis)Clinical
- 3 nov. 2026Q3 2026 resultsEarnings
- 2026Annual general meetingAGM
Governance
International leadership from European ophthalmology industry. Mixed board (Switzerland, United States). The DIAMOND episode particularly highlights the importance of shareholder dialogue: clarity on the strategic pivot, capital allocation after the failure, governance of the remaining portfolio. CapCordia documents AGM resolutions, votes and financial communications in French for francophone shareholders.
Encounters
- 28 July 2026Conversation with the CEO— Riad Sherif, Chief Executive Officer of Oculis
Video conference organised by CapCordia with shareholders, following the DIAMOND trial results and the strategic refocus.
This file is editorial and does not constitute investment advice. Individual shareholders are responsible for their own decisions.